Free Trial

BioLife Solutions (BLFS) Competitors

BioLife Solutions logo
$21.55 +0.46 (+2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$21.56 +0.00 (+0.02%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BLFS vs. IRTC, TMDX, MMED, LIVN, and LQDA

Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include iRhythm Technologies (IRTC), TransMedics Group (TMDX), MiniMed Group (MMED), LivaNova (LIVN), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry.

How does BioLife Solutions compare to iRhythm Technologies?

BioLife Solutions (NASDAQ:BLFS) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, iRhythm Technologies had 35 more articles in the media than BioLife Solutions. MarketBeat recorded 36 mentions for iRhythm Technologies and 1 mentions for BioLife Solutions. iRhythm Technologies' average media sentiment score of 0.43 beat BioLife Solutions' score of 0.34 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
iRhythm Technologies
8 Very Positive mention(s)
10 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioLife Solutions has higher earnings, but lower revenue than iRhythm Technologies. BioLife Solutions is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$96.21M10.95-$4.59M-$0.11N/A
iRhythm Technologies$787.85M4.93-$44.55M-$0.86N/A

iRhythm Technologies has a net margin of -3.53% compared to BioLife Solutions' net margin of -4.50%. BioLife Solutions' return on equity of 1.71% beat iRhythm Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions-4.50% 1.71% 1.54%
iRhythm Technologies -3.53%-10.26%-1.39%

BioLife Solutions has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 1.1% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioLife Solutions presently has a consensus price target of $32.00, indicating a potential upside of 48.49%. iRhythm Technologies has a consensus price target of $193.38, indicating a potential upside of 63.73%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

Summary

iRhythm Technologies beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TransMedics Group presently has a consensus price target of $152.33, indicating a potential upside of 60.47%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 48.49%. Given TransMedics Group's higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.58
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, TransMedics Group had 6 more articles in the media than BioLife Solutions. MarketBeat recorded 7 mentions for TransMedics Group and 1 mentions for BioLife Solutions. TransMedics Group's average media sentiment score of 0.83 beat BioLife Solutions' score of 0.34 indicating that TransMedics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

TransMedics Group has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$605.49M5.41$190.29M$4.9019.37
BioLife Solutions$96.21M10.95-$4.59M-$0.11N/A

TransMedics Group has a net margin of 31.43% compared to BioLife Solutions' net margin of -4.50%. TransMedics Group's return on equity of 30.17% beat BioLife Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group31.43% 30.17% 11.39%
BioLife Solutions -4.50%1.71%1.54%

Summary

TransMedics Group beats BioLife Solutions on 14 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and BioLife Solutions (NASDAQ:BLFS) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiniMed Group presently has a consensus price target of $22.45, indicating a potential upside of 92.25%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 48.49%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.85
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, MiniMed Group had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for MiniMed Group and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.34 beat MiniMed Group's score of 0.20 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiniMed Group has higher revenue and earnings than BioLife Solutions.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$2.99B1.10N/AN/AN/A
BioLife Solutions$96.21M10.95-$4.59M-$0.11N/A

MiniMed Group has a net margin of 0.00% compared to BioLife Solutions' net margin of -4.50%. BioLife Solutions' return on equity of 1.71% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
BioLife Solutions -4.50%1.71%1.54%

Summary

BioLife Solutions beats MiniMed Group on 7 of the 13 factors compared between the two stocks.

How does BioLife Solutions compare to LivaNova?

LivaNova (NASDAQ:LIVN) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

LivaNova presently has a consensus price target of $74.78, indicating a potential upside of 29.85%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 48.49%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, LivaNova and LivaNova both had 1 articles in the media. BioLife Solutions' average media sentiment score of 0.34 beat LivaNova's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LivaNova
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

97.6% of LivaNova shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

BioLife Solutions has lower revenue, but higher earnings than LivaNova. BioLife Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.39B2.28-$242.47M-$4.46N/A
BioLife Solutions$96.21M10.95-$4.59M-$0.11N/A

BioLife Solutions has a net margin of -4.50% compared to LivaNova's net margin of -17.46%. LivaNova's return on equity of 16.54% beat BioLife Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
LivaNova-17.46% 16.54% 7.30%
BioLife Solutions -4.50%1.71%1.54%

Summary

BioLife Solutions beats LivaNova on 10 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to Liquidia?

Liquidia (NASDAQ:LQDA) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Liquidia presently has a consensus price target of $43.44, indicating a potential upside of 8.26%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 48.49%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liquidia
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.75
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Liquidia had 12 more articles in the media than BioLife Solutions. MarketBeat recorded 13 mentions for Liquidia and 1 mentions for BioLife Solutions. Liquidia's average media sentiment score of 0.59 beat BioLife Solutions' score of 0.34 indicating that Liquidia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Liquidia
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

64.5% of Liquidia shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 26.5% of Liquidia shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Liquidia has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

BioLife Solutions has lower revenue, but higher earnings than Liquidia. BioLife Solutions is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liquidia$158.32M22.53-$68.92M-$0.83N/A
BioLife Solutions$96.21M10.95-$4.59M-$0.11N/A

BioLife Solutions has a net margin of -4.50% compared to Liquidia's net margin of -43.53%. BioLife Solutions' return on equity of 1.71% beat Liquidia's return on equity.

Company Net Margins Return on Equity Return on Assets
Liquidia-43.53% -209.33% -25.32%
BioLife Solutions -4.50%1.71%1.54%

Summary

BioLife Solutions beats Liquidia on 9 of the 17 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLFS vs. The Competition

MetricBioLife SolutionsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.05B$8.14B$6.25B$11.87B
Dividend YieldN/A2.45%2.73%5.21%
P/E Ratio-195.89119.7329.0428.47
Price / Sales10.957.42476.6160.92
Price / Cash92.6317.3227.6236.52
Price / Book2.793.529.676.67
Net Income-$4.59M$223.69M$3.55B$332.53M
7 Day Performance3.11%0.07%1.70%2.01%
1 Month Performance10.46%10.32%5.62%9.19%
1 Year Performance-10.95%0.92%34.41%39.59%

BioLife Solutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLFS
BioLife Solutions
2.9714 of 5 stars
$21.55
+2.2%
$32.00
+48.5%
N/A$1.05B$96.21MN/A440
IRTC
iRhythm Technologies
2.8745 of 5 stars
$125.96
+3.0%
$202.92
+61.1%
N/A$4.02B$747.14MN/A2,400
TMDX
TransMedics Group
4.6137 of 5 stars
$108.12
-2.5%
$152.33
+40.9%
N/A$3.83B$605.49M22.07210
MMED
MiniMed Group
N/A$12.92
-2.1%
$22.45
+73.8%
N/A$3.63B$2.99BN/A8,000
LIVN
LivaNova
2.2187 of 5 stars
$63.41
-1.2%
$74.78
+17.9%
N/A$3.51B$1.39BN/A3,300

Related Companies and Tools


This page (NASDAQ:BLFS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners